Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
TL;DR
- Eli Lilly's combination therapy of eloralintide and tirzepatide showed greater weight loss than tirzepatide alone in a mid-stage trial.
- The combo regimen resulted in an average weight loss of up to 23.3%, compared to 14.8% for tirzepatide alone.
- The combination treatment also improved A1C levels more effectively than either drug individually.
- A higher percentage of patients on the combo regimen discontinued treatment due to side effects, primarily gastrointestinal.
- Lilly plans to adjust dosing and advance the combination therapy into Phase 3 trials by the end of the year.
- The company is also developing a co-formulation for a single injection of both drugs.
- The combination targets three hormone pathways: GLP-1, GIP, and amylin.